MX2022008623A - Una combinacion farmaceutica para el tratamiento de un cancer. - Google Patents

Una combinacion farmaceutica para el tratamiento de un cancer.

Info

Publication number
MX2022008623A
MX2022008623A MX2022008623A MX2022008623A MX2022008623A MX 2022008623 A MX2022008623 A MX 2022008623A MX 2022008623 A MX2022008623 A MX 2022008623A MX 2022008623 A MX2022008623 A MX 2022008623A MX 2022008623 A MX2022008623 A MX 2022008623A
Authority
MX
Mexico
Prior art keywords
treatment
cancer
pharmaceutical combination
abtl0812
chemotherapy
Prior art date
Application number
MX2022008623A
Other languages
English (en)
Inventor
Coriat José Alberto Alfón
Montoyo Héctor Pérez
Velasco Marc Yeste
Guardiola Pau Muñoz
Garcia Carles Domènech
Salinas Guillermo Yoldi
De La Vega Jose Miguel Lizcano
Guinard Miguel Francisco Segura
Coderch Laia Paris
Claudio Festuccia
Original Assignee
Ability Pharmaceuticals S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ability Pharmaceuticals S L filed Critical Ability Pharmaceuticals S L
Publication of MX2022008623A publication Critical patent/MX2022008623A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Uso de ABTL0812 en el tratamiento de un cáncer en un paciente humano, en donde el tratamiento del cáncer se relaciona con quimioterapia, tratamiento de terapia dirigida, tratamiento de inmunoterapia o tratamiento con radioterapia.
MX2022008623A 2020-02-10 2021-02-10 Una combinacion farmaceutica para el tratamiento de un cancer. MX2022008623A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382089 2020-02-10
PCT/EP2021/053162 WO2021160650A1 (en) 2020-02-10 2021-02-10 A pharmaceutical combination for the treatment of a cancer

Publications (1)

Publication Number Publication Date
MX2022008623A true MX2022008623A (es) 2022-08-08

Family

ID=69770809

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008623A MX2022008623A (es) 2020-02-10 2021-02-10 Una combinacion farmaceutica para el tratamiento de un cancer.

Country Status (14)

Country Link
US (1) US20230088704A1 (es)
EP (1) EP4103170A1 (es)
JP (1) JP2023514036A (es)
KR (1) KR20220140723A (es)
CN (1) CN114980879A (es)
AU (1) AU2021220258A1 (es)
BR (1) BR112022014074A2 (es)
CA (1) CA3163864A1 (es)
CL (1) CL2022002064A1 (es)
IL (1) IL295067A (es)
MX (1) MX2022008623A (es)
TW (1) TW202139992A (es)
WO (1) WO2021160650A1 (es)
ZA (1) ZA202207243B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
CA3063625A1 (en) 2017-05-16 2018-11-22 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer

Also Published As

Publication number Publication date
EP4103170A1 (en) 2022-12-21
JP2023514036A (ja) 2023-04-05
ZA202207243B (en) 2023-03-29
BR112022014074A2 (pt) 2022-09-13
IL295067A (en) 2022-09-01
CN114980879A (zh) 2022-08-30
AU2021220258A1 (en) 2022-06-30
TW202139992A (zh) 2021-11-01
KR20220140723A (ko) 2022-10-18
CL2022002064A1 (es) 2023-02-03
WO2021160650A1 (en) 2021-08-19
CA3163864A1 (en) 2021-08-19
US20230088704A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
MX2020009773A (es) Terapia de combinacion.
EP4171548A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
MX2021014137A (es) Pertuzumab para usarse en el tratamiento de cancer de mama her2 positivo.
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MX2020001727A (es) Terapia de combinacion.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
MX2019003751A (es) Proteina terapeutica.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
ZA200600188B (en) Combination therapy
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
IL177953A0 (en) Combination therapy including azd2171 and a taxane
MX2021006778A (es) Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion.
MX2020013883A (es) Tratamientos oncológicos con agentes de zinc.
MX2022008623A (es) Una combinacion farmaceutica para el tratamiento de un cancer.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2018011607A (es) Sultiame para el tratamiento de apnea del sueño.
MX2019014842A (es) Uso de una combinación de ivosidenib y radiación para tratar gliomas.
MX2021001764A (es) Terapia de combinacion.
MX2019014934A (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.